Compare Regeneron Pharmaceuticals Inc (REGN) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Wheaton Precious Metals Corp trades at $137.77 (market cap $60.84B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Wheaton Precious Metals Corp pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Wheaton Precious Metals Corp for 66 Days on average.
| REGN | WPM | |
|---|---|---|
Market Cap | $76.40B | $60.84B |
Volume | 626,381 | 1,408,370 |
Sector | Health | Basic Materials |
52-Week High | $852.03 | $165.72 |
52-Week Low | $557.73 | $94.37 |
Typical Hold Time | 107 Days | 66 Days |
Enterprise Value | $71.12B | $62.71B |
Dividend Yield | 0.51% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Wheaton Precious Metals (WPM) trades at $134.96, down 1.95% on the day, amid a bearish technical signal. The company reported record revenues of $2.31B in 2025, with net income surging to $1.47B, and has beaten EPS estimates for three consecutive quarters. Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive with strong analyst support—80% recommend Buy and a consensus price target of $164.80 implies 22% upside. Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock's current valuation multiples are elevated, but robust cash flow and margin expansion underpin the bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
